Magnetic Nanoparticles Market Research Report Forecast to 2030

TABLE OF CONTENTS 1 MARKET INTRODUCTION ...................................................................................... 13 1.1 DEFINITION.............................................................................................................................. 13 1.2 SCOPE OF THE STUDY ............................................................................................................. 13 1.3 RESEARCH OBJECTIVE ............................................................................................................ 14 1.4 MARKET STRUCTURE ............................................................................................................... 14 1.5 LIST OF ASSUMPTIONS ............................................................................................................ 15 2 MARKET DYNAMICS ............................................................................................... 16 2.1 OVERVIEW ............................................................................................................................... 16 2.2 DRIVERS .................................................................................................................................. 17 2.2.1 EXPANSION OF BIOMEDICAL AND HEALTHCARE SECTOR IN US ................................ 17 2.2.2 EXPANSION OF BIOMEDICAL AND HEALTHCARE SECTOR IN CHINA .......................... 18 2.2.3 INCREASE USAGE OF MAGNETIC NANOPARTICLES TECHNOLOGY IN PRETREATMENT KITS ............................................................................................. 20 2.3 RESTRAINTS ............................................................................................................................ 22 2.3.1 FLUCTUATIONS IN THE PRICES OF MAGNETIC NANOPARTICLES MATERIALS IN CHINA ............................................................................................................... 22 2.3.2 FLUCTUATIONS IN THE PRICES OF MAGNETIC NANOPARTICLES MATERIALS IN US ..................................................................................................................... 24 2.3.3 TOXICITY AND BIOCOMPATIBILITY OF MAGNETIC NANOPARTICLES MATERIALS ...... 26 2.4 OPPORTUNITIES ...................................................................................................................... 28 2.4.1 INCREASING USE OF MAGNETIC NANOPARTICLES FOR WATER TREATMENT ............. 28 2.5 TRENDS ................................................................................................................................... 29 2.5.1 CORE TECHNOLOGY OF MAGNETIC NANOPARTICLES THAT CAN SEPARATE AND CONCENTRATE TARGET PATHOGENS THROUGH MAGNETISM .......................... 29 2.5.2 NANODIAGNOSTIC TECHNOLOGIES FOR SEPSIS USING MAGNETIC NANOPARTICLES (MNPS) ....................................................................................... 31 3 QUALITATIVE ANALYSIS ON FUNCTIONAL GROUP AND SIZE FOR MAGNETIC NANOPARTICLES ....................................................................... 35 3.1 BY FUNCTIONAL GROUP .......................................................................................................... 35 3.2 BY SIZE .................................................................................................................................... 37 3.3 OVERVIEW OF MAGNETIC BEAD-BASED METHOD EMPLOYED IN BIO-DIAGNOSTICS .................. 39 4 COMPETITIVE LANDSCAPE ................................................................................... 41 4.1 INTRODUCTION ........................................................................................................................ 41 4.2 COMPETITIVE ANALYSIS.......................................................................................................... 42 4.3 MARKET SHARE ANALYSIS ...................................................................................................... 43 4.4 MAJOR GROWTH STRATEGY IN THE MAGNETIC NANOPARTICES MARKET (BIO-DIAGNOSTIC END USERS) .................................................................................................. 43 4.5 COMPETITIVE BENCHMARKING ............................................................................................... 44 4.6 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN MAGNETIC NANOPARTICLES MARKET ........................................................................................................ 46 4.7 KEY DEVELOPMENTS & GROWTH STRATEGIES ......................................................................... 47 4.7.1 PRODUCT LAUNCH/ PRODUCT DEVELOPMENT ........................................................ 47 4.7.2 PARTNERSHIP/COLLABORATION ............................................................................ 48 4.8 MAJOR PLAYER FINANCIAL* .................................................................................................... 49 4.8.1 SALES, OPERATING INCOME, R&D EXPENDITURE 2022* ........................................... 49 5 COMPANY PROFILES ............................................................................................. 50 5.1 QIAGEN NV .............................................................................................................................. 50 5.1.1 COMPANY OVERVIEW ............................................................................................. 50 5.1.2 FINANCIAL OVERVIEW ............................................................................................ 51 5.1.3 PRODUCTS OFFERED .............................................................................................. 52 5.1.4 KEY DEVELOPMENTS ............................................................................................. 53 5.1.5 SWOT ANALYSIS .................................................................................................... 53 5.1.6 KEY STRATEGIES .................................................................................................... 54 5.2 BIONEER CORPORATION .......................................................................................................... 55 5.2.1 COMPANY OVERVIEW ............................................................................................. 55 5.2.2 FINANCIAL OVERVIEW ............................................................................................ 55 5.2.3 PRODUCTS OFFERED .............................................................................................. 56 5.2.4 KEY DEVELOPMENTS ............................................................................................. 57 5.2.5 SWOT ANALYSIS .................................................................................................... 57 5.2.6 KEY STRATEGIES .................................................................................................... 58 5.3 T2 BIOSYSTEMS, INC. .............................................................................................................. 59 5.3.1 COMPANY OVERVIEW ............................................................................................. 59 5.3.2 FINANCIAL OVERVIEW ............................................................................................ 59 5.3.3 PRODUCTS OFFERED .............................................................................................. 60 5.3.4 KEY DEVELOPMENTS ............................................................................................. 60 5.3.5 SWOT ANALYSIS .................................................................................................... 61 5.3.6 KEY STRATEGIES .................................................................................................... 61 5.4 THERMO FISHER SCIENTIFIC INC. ............................................................................................ 62 5.4.1 COMPANY OVERVIEW ............................................................................................. 62 5.4.2 FINANCIAL OVERVIEW ............................................................................................ 63 5.4.3 PRODUCTS OFFERED .............................................................................................. 64 5.4.4 KEY DEVELOPMENTS ............................................................................................. 65 5.4.5 SWOT ANALYSIS .................................................................................................... 65 5.4.6 KEY STRATEGIES .................................................................................................... 65 5.5 HOFFMANN-LA ROCHE LTD...................................................................................................... 66 5.5.1 FINANCIAL OVERVIEW ............................................................................................ 67 5.5.2 PRODUCTS OFFERED .............................................................................................. 68 5.5.3 KEY DEVELOPMENTS ............................................................................................. 68 5.5.4 SWOT ANALYSIS .................................................................................................... 69 5.5.5 KEY STRATEGIES .................................................................................................... 69 5.6 CREATIVE BIOGENE ................................................................................................................. 70 5.6.1 COMPANY OVERVIEW ............................................................................................. 70 5.6.2 FINANCIAL OVERVIEW ............................................................................................ 70 5.6.3 PRODUCTS OFFERED .............................................................................................. 71 5.6.4 KEY DEVELOPMENTS ............................................................................................. 71 5.6.5 SWOT ANALYSIS .................................................................................................... 72 5.6.6 KEY STRATEGIES .................................................................................................... 72 5.7 MAGGENOME TECHNOLOGIES PVT. LTD. ................................................................................. 73 5.7.1 COMPANY OVERVIEW ............................................................................................. 73 5.7.2 FINANCIAL OVERVIEW ............................................................................................ 73 5.7.3 PRODUCTS OFFERED .............................................................................................. 74 5.7.4 KEY DEVELOPMENTS ............................................................................................. 75 5.7.5 SWOT ANALYSIS .................................................................................................... 75 5.7.6 KEY STRATEGIES .................................................................................................... 76 5.8 DAAN GENE CO., LTD. .............................................................................................................. 77 5.8.1 COMPANY OVERVIEW ............................................................................................. 77 5.8.2 FINANCIAL OVERVIEW ............................................................................................ 77 5.8.3 PRODUCTS OFFERED .............................................................................................. 78 5.8.4 KEY DEVELOPMENTS ............................................................................................. 78 5.8.5 SWOT ANALYSIS .................................................................................................... 79 5.8.6 KEY STRATEGIES .................................................................................................... 79 5.9 MAGBIO GENOMICS INC. ......................................................................................................... 80 5.9.1 COMPANY OVERVIEW ............................................................................................. 80 5.9.2 FINANCIAL OVERVIEW ............................................................................................ 80 5.9.3 PRODUCTS OFFERED .............................................................................................. 81 5.9.4 KEY DEVELOPMENTS ............................................................................................. 81 5.9.5 SWOT ANALYSIS .................................................................................................... 82 5.9.6 KEY STRATEGIES .................................................................................................... 82 5.10 BECKMAN COULTER INC. (DANAHER CORPORATION) .............................................................. 83 5.10. COMPANY OVERVIEW ............................................................................................. 83 5.10. FINANCIAL OVERVIEW ............................................................................................ 84 5.10. PRODUCTS OFFERED .............................................................................................. 85 5.10.4KEY DEVELOPMENTS ............................................................................................. 85 5.10.5SWOT ANALYSIS .................................................................................................... 86 5.10.6KEY STRATEGIES.................................................................................................... 86 5.11 XI'AN TIANLONG SCIENCE AND TECHNOLOGY CO., LTD ........................................................... 87 5.11.1COMPANY OVERVIEW ............................................................................................. 87 5.11.2FINANCIAL OVERVIEW ............................................................................................ 87 5.11.3PRODUCTS OFFERED .............................................................................................. 88 5.11.4KEY DEVELOPMENTS ............................................................................................. 90 5.11.5SWOT ANALYSIS .................................................................................................... 90 5.11.6KEY STRATEGIES.................................................................................................... 90 5.12 GUANGZHOU DONGSHENG BIOTECH CO., LTD ......................................................................... 91 5.12.1COMPANY OVERVIEW ............................................................................................. 91 5.12.2FINANCIAL OVERVIEW ............................................................................................ 91 5.12.3PRODUCTS OFFERED .............................................................................................. 92 5.12.4KEY DEVELOPMENTS ............................................................................................. 92 5.12.5SWOT ANALYSIS .................................................................................................... 92 5.12.6KEY STRATEGIES.................................................................................................... 93 5.13 GENEAID BIOTECH LTD. ........................................................................................................... 94 5.13.1COMPANY OVERVIEW ............................................................................................. 94 5.13.2FINANCIAL OVERVIEW ............................................................................................ 94 5.13.3PRODUCTS OFFERED .............................................................................................. 95 5.13.4KEY DEVELOPMENTS ............................................................................................. 95 5.13.5SWOT ANALYSIS .................................................................................................... 96 5.13.6KEY STRATEGIES.................................................................................................... 97 5.14 TIANGEN BIOTECH(BEIJING)CO., LTD.98 5.14.1COMPANY OVERVIEW ............................................................................................. 98 5.14.2FINANCIAL OVERVIEW ............................................................................................ 98 5.14.3PRODUCTS OFFERED .............................................................................................. 99 5.14.4KEY DEVELOPMENTS ............................................................................................. 99 5.14.5SWOT ANALYSIS .................................................................................................... 100 5.14.6KEY STRATEGIES.................................................................................................... 100 5.15 WUXI NEST BIOTECHNOLOGY CO., LTD .................................................................................... 101 5.15.1COMPANY OVERVIEW ............................................................................................. 101 5.15.2FINANCIAL OVERVIEW ............................................................................................ 101 5.15.3PRODUCTS OFFERED .............................................................................................. 102 5.15.4KEY DEVELOPMENTS ............................................................................................. 102 5.15.5SWOT ANALYSIS .................................................................................................... 103 5.15.6KEY STRATEGIES.................................................................................................... 103

LIST OF TABLES TABLE 1 LIST OF ASSUMPTIONS 15 TABLE 2 PRODUCT LAUNCH/PRODUCT DEVELOPMENT 47 TABLE 3 PARTNERSHIP/COLLABORATION 48 TABLE 4 SALES, OPERATING INCOME, R & D EXPENDITURE 2022 49 TABLE 5 QIAGEN N.V.: PRODUCTS OFFERED 52 TABLE 6 QIAGEN N. V.: KEY DEVELOPMENTS 53 TABLE 7 BIONEER CORPORATION: PRODUCTS OFFERED 56 TABLE 8 BIONEER CORPORATION: KEY DEVELOPMENTS 57 TABLE 9 T2 BIOSYSTEMS, INC.: PRODUCTS OFFERED 60 TABLE 10 T2 BIOSYSTEMS, INC.: KEY DEVELOPMENTS 60 TABLE 11 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 64 TABLE 12 HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 68 TABLE 13 CREATIVE BIOGENE: PRODUCTS OFFERED 71 TABLE 14 MAGGENOME TECHNOLOGIES PVT. LTD.: PRODUCTS OFFERED 74 TABLE 15 MAGGENOME TECHNOLOGIES PVT. LTD.: KEY DEVELOPMENTS 75 TABLE 16 DAAN GENE CO., LTD: PRODUCTS OFFERED 78 TABLE 17 MAGBIO GENOMICS INC.: PRODUCTS OFFERED 81 TABLE 18 BECKMAN COULTER INC. (DANAHER CORPORATION): PRODUCTS OFFERED 85 TABLE 19 BECKMAN COULTER INC. (DANAHER CORPORATION): KEY DEVELOPMENTS 85 TABLE 20 XI'AN TIANLONG SCIENCE AND TECHNOLOGY CO., LTD: PRODUCTS OFFERED 88 TABLE 21 GUANGZHOU DONGSHENG BIOTECH CO., LTD: PRODUCTS OFFERED 92 TABLE 22 GENEAID BOITECH LTD.: PRODUCTS OFFERED 95 TABLE 23 GENEAID BOITECH LTD.: KEY DEVELOPMENTS 95 TABLE 24 TIANGEN BIOTECH (BEIJING) CO., LTD.: PRODUCTS OFFERED 99 TABLE 25 WUXI NEST BIOTECHNOLOGY CO., LTD.: PRODUCTS OFFERED 102 LIST OF FIGURES FIGURE 1 MAGNETIC NANOPARTICLES MARKET: MARKET STRUCTURE 14 FIGURE 2 MARKET DYNAMICS: US AND CHINA MAGNETIC NANOPARTICLES MARKET 16 FIGURE 3 MARKET SIZE OF BIOMEDICAL INDUSTRY IN CHINA FROM 2015 TO 2019 (BILLION YUAN) 18 FIGURE 4 USE OF MNPS FOR BIOMEDICAL APPLICATIONS 19 FIGURE 5 SCHEMATIC PROCEDURE FOR NUCLEIC ACID PURIFICATION BY MEANS OF MAGNETIC NANOPARTICLE (MNPS) 21 FIGURE 6 DRIVERS: IMPACT ANALYSIS 22 FIGURE 7 PRICES FOR IRON ORE MARKET IN CHINA, 2019-2022, USD PER TONS 23 FIGURE 8 PRICES FOR IRON ORE MARKET IN US, 2019-2022, USD PER TONS 25 FIGURE 9 RESTRAINT: IMPACT ANALYSIS 27 FIGURE 10 RESTRAINT: IMPACT ANALYSIS 28 FIGURE 11 NANODIAGNOSTIC TECHNOLOGIES FOR SEPSIS USING MAGNETIC NANOPARTICLES (MNPS) 31 FIGURE 12 FIGURE A) REPRESENTS SCHEMATIC REPRESENTATION OF T2MR DIAGNOSTIC PLATFORM 32 FIGURE 13 FIGURE B) REPRESENTS NANOMAGNETO-DNA ASSAY FOR THE DETECTION OF BACTERIAL 16S RRNA 33 FIGURE 14 FIGURE C) REPRESENTS SERS SUBSTRATES TO ANCHOR ANTIBODY-DECORATED 34 FIGURE 15 MARKET SHARE ANALYSIS, 2022 43 FIGURE 16 COMPETITIVE BENCHMARKING 44 FIGURE 17 COMPETITIVE BENCHMARKING 45 FIGURE 18 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN MAGNETIC NANOPARTICLES MARKET (BIO-DIAGNOSTIC COMPANIES) 46 FIGURE 19 QIAGEN N. V.: FINANCIAL OVERVIEW SNAPSHOT 51 FIGURE 22 T2 BIOSYSTEMS, INC.: FINANCIAL OVERVIEW SNAPSHOT 59 FIGURE 24 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT 63 FIGURE 26 HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 67 FIGURE 29 MAGGENOME TECHNOLOGIES PVT. LTD.: SWOT ANALYSIS 75 FIGURE 30 DAAN GENE CO., LTD: SWOT ANALYSIS 79 FIGURE 32 BECKMAN COULTER INC. (DANAHER CORPORATION): FINANCIAL OVERVIEW SNAPSHOT 84 FIGURE 33 BECKMAN COULTER INC. (DANAHER CORPORATION): SWOT ANALYSIS 86